The CAR-T field has a persistence problem. T cells get exhausted. They stop working. The tumor wins.
Verismo Therapeutics thinks the fix is in the signaling architecture itself. Instead of the standard CD28 or 4-1BB costimulatory domains that every other CAR-T uses, Verismo built its platform on killer immunoglobulin-like receptor (KIR) signaling, the biology that natural killer cells use to stay active and avoid burnout.
The company calls it KIR-CAR. It’s a modular, multi-chain system designed to improve T cell persistence, reduce exhaustion, and give more controlled activation. And it now has $28 million from HLB Innovation to prove it works in humans.
Verismo Therapeutics KIR-CAR pipeline
SynKIR-110
CAR-T · Mesothelin-targeting · Solid tumors (ovarian, mesothelioma, cholangiocarcinoma)
SynKIR-310
CAR-T · CD19-targeting · B-cell non-Hodgkin lymphoma
AACR 2026 data expected for SynKIR-110
Two programs are running in the clinic right now. SynKIR-110 targets mesothelin-expressing solid tumors, covering ovarian cancer, mesothelioma, and cholangiocarcinoma. SynKIR-310 goes after CD19 in B-cell non-Hodgkin lymphoma.
The timing matters here. Initial clinical data from SynKIR-110 is set to drop at AACR 2026. That means the $28 million from HLB isn’t speculative. It’s fuel for a company about to show the world whether KIR signaling biology translates from bench to bedside.
The allogeneic CAR-T wave is getting all the attention right now, with companies like Allogene posting data that’s turning heads. But Verismo’s bet is different. They’re not changing the cell source. They’re changing the wiring.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
If the AACR data shows meaningful activity in solid tumors with manageable safety, Verismo’s KIR-CAR approach could become a serious contender in the next generation of engineered cell therapies. Philadelphia-based, two assets in clinic, and a data readout weeks away. Keep an eye on this one.
